Welcome!

News Feed Item

Imprimis Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Operational Update

SAN DIEGO, Aug. 13, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients pursuant to prescriptions for individually identified patients at accessible prices, today announced selected financial results for the quarter ended June 30, 2014, and provided an update on recent operations.

"During the second quarter we made significant progress in three key business areas," said Mark L. Baum, Chief Executive Officer of Imprimis. "First, we completed the acquisition and integration of our first prescription fulfillment pharmacy.  Second, we expanded distribution of our proprietary sterile ophthalmic formulations to 33 states and territories across the United States.  Third, our corporate development team has positioned the company to expand into a new therapeutic area which we hope to invest in during 2015." Mr. Baum continued, "As a result of the need to expand our supply capacity and create redundancy in our prescription fulfillment operations, during the second half of the year, we expect to continue to pursue opportunities to acquire existing businesses that we believe will be strategically and fiscally accretive.  This quarter's accomplishments were key to laying the foundation for our ability to deliver on the objectives of our unique business model, in ophthalmology and in other therapeutic areas, which we believe will advance pharmaceutical innovation while delivering near-term and affordable healthcare solutions to Americans."

Selected highlights regarding results for the quarter ended June 30, 2014 follow:

Ophthalmology Business

"We are very encouraged by the strong interest level in Dropless therapy by leading ophthalmologists from across the country, including many high volume practices. This initial response to our proprietary formulations can be attributed to addressing the convergence of unmet needs from patients, practitioners and payers alike. As new key metropolitan areas are added to our list of licensed locations, we expect to increase the velocity of adoption," stated John Saharek, Imprimis' Vice-President of Commercialization. 

  • Imprimis' patent-pending drug formulations, containing triamcinolone acetonide and moxifloxacin hydrochloride (Tri-Moxi), and added vancomycin (Tri-Moxi-Vanc) are available today and are being prescribed by leading ophthalmologists in ambulatory surgery centers across the country. These formulations are primarily being prescribed by physicians for cataract surgery patients today pursuant to prescriptions for individually identified patients, but have application in many other ocular surgeries.
  • Since commercial efforts began in April 2014, almost 100 ophthalmologists from across the country have been either trained or have begun to prescribe our formulations for their individual patients, realizing the many advantages to the patient of administering an easily injectable combination corticosteroid and antibiotic during surgery. These advantages include virtually eliminating patient compliance issues with self-administered eye drop regimens; and may include reducing staff time and chair time spent on instructions, follow-ups with post-operative surgical patients and call-backs from pharmacists. This is driving an increased interest by many ophthalmic practices to incorporate Dropless therapy to serve their patients' need and create new efficiencies in the practices. During the third quarter, we expect Dropless therapy will be evaluated and/or initiated at a number of major ambulatory surgery centers that represent over 50,000 cataract procedures annually.
  • Imprimis' patent-pending Dropless ophthalmic formulations have now been referenced in over 36 trade press print and on-line articles since January 2014. There have been multiple presentations on Dropless therapy at major clinical and scientific meetings. Furthermore, the company recently shared results of a survey of leading national cataract surgeons that showed 20 out of the 21 physicians surveyed expressed favorable opinions to the concept of Imprimis' single intraocular injection administered at the conclusion of cataract surgery.(1) These surgeons' perspectives examine the benefits of Dropless cataract surgery for both doctors and patients. Specifically, the surgeons highlighted attributes related to convenience and compliance. To watch the complete video interviews, please visit www.GoDropless.com/why-go-dropless.

Corporate Development

  • In preparation to launch a second business unit in urology during 2015, we are conducting preliminary research on our patent-pending injectable pentoxifylline formulation (PTX-110) into patients suffering from Peyronie's Disease started during the first quarter of 2014. The preliminary results of this research have revealed sufficient data that may warrant the design of a larger, follow-on proof-of-concept study. We expect to provide a summary report of the results of this important preliminary research as well as the clinical and commercial development plans for PTX-110 going forward, during the second half of 2014. Peyronie's Disease, which according to the Brady Urological Institute at The Johns Hopkins Hospital, affects approximately 1 in 11 men, is a connective tissue disorder involving the growth of fibrous plaques in the soft tissue of the penis.
  • In order to protect our formulations, our innovation team has filed a total of 5 non-provisional utility patent applications (plus 4 PCT applications covering the same subject matter) and 4 US provisional patent applications during the first half of 2014.
  • We expect to provide a summary in the near term of ongoing evaluations of our proprietary formulations related to their expansion into other markets and therapeutic areas.

Pharmacy Operations

  • Immediately following our acquisition of Pharmacy Creations on April 1, 2014, we began implementing new internal quality assurance standards and best practice policies that we believe may exceed those required under the U.S. Pharmacopeia (USP) and state pharmacy laws in certain important respects. These standards and policies include, among other things, the engagement of a third party quality assurance and quality control consultant to perform quarterly inspections of our pharmacy operations, including assessing compliance with USP, state board of pharmacy standards and environmental monitoring. We also implemented a policy to validate that formulations produced at Pharmacy Creations satisfy USP guidelines and specifications prior to shipment to patients and physicians through testing at a third party FDA registered laboratory. We limited the sales of certain pharmacy products and formulations during the month of July 2014 while fully implementing these practices.
  • We expect to continue to develop ownership of or access to a network of prescription fulfillment pharmacies and potentially, outsourcing facilities registered with the FDA under section 503B of the Federal Food, Drug and Cosmetic Act, to formulate and distribute not only our proprietary compounded formulations, but also other non-proprietary drug formulations within our therapeutic areas of interest.

Second Quarter 2014 Financial Results

"We are excited that following the commencement of our pharmacy operations on April 1, 2014, we began recording revenues from sales for the first time in the company's history.  These revenues include sales of our proprietary ophthalmic formulations and other non-proprietary pharmacy products.  As our strategy evolves and matures, we expect to recognize the benefits of the capital efficiency of our business model.  During the quarter ended June 30, while maintaining our cash management policies we were able to start recognizing revenues from the sale of our formulations and shift some of our expenses from research and development to selling and marketing.  This shift demonstrates how we efficiently move formulations through the various stages of our unique commercialization model," stated Andrew Boll, Imprimis' Vice-President of Accounting and Public Reporting. 

The company's financial results are summarized below:


For the three months
ended June 30, 2014

For the three months
ended June 30, 2013

Total Revenues

$      667,701

$          2,500

Cost of Pharmacy Sales

$      476,549

$                  -

Selling & Marketing Expenses

$      469,188

$                  -

General & Administrative Expenses

$   2,289,233

$   1,556,145

Research & Development Expenses

$        35,571

$      677,347

Other Income

$          7,115

$        12,940

Net Loss

$ (2,595,725)

$ (2,218,052)

Net Loss per Common Share

$          (0.28)

$          (0.25)

 


For the six months
ended June 30, 2014

For the six months
ended June 30, 2013

Total Revenues

$      669,011

$          5,000

Cost of Pharmacy Sales

$      476,549

$                  -

Selling & Marketing Expenses

$      825,896

$                  -

General & Administrative Expenses

$   4,209,255

$   2,576,094

Research & Development Expenses

$        95,723

$   1,132,447

Other Income

$        17,424

$        20,008

Net Loss

$ (4,920,888)

$ (3,683,533)

Net Loss per Common Share

$          (0.54)

$          (0.44)

 

Cash and cash equivalents at June 30, 2014, totaled $12.1 million compared to $14.2 million at March 31, 2014.  Imprimis used approximately $1.5 million in operating activities and approximately $0.7 million in investing activities, which included cash used for the acquisition of Pharmacy Creations and purchase of restricted investments during the three months ended June 30, 2014.  Imprimis also received approximately $0.1 million from the exercise of stock options and warrants during the second quarter.

ABOUT IMPRIMIS PHARMACEUTICALS

We are a vertically-integrated specialty pharmaceutical company focused on the development and commercialization of innovative proprietary sterile and topical drug formulations. We own proprietary formulations in ophthalmology, urology and wound management that we believe may offer advantages over commercially available formulations or which serve substantially unmet needs in the marketplace.  We are currently focused on developing our proprietary ophthalmology formulation business.  We also sell non-proprietary sterile and topical drug formulations.  We fulfill prescription orders for our drug formulations through our New Jersey-based prescription fulfillment facility, which is licensed to distribute our drug formulations in 33 states and territories.  We believe our business model allows us to meet the realities of the current health care economy by offering quality pharmaceutical innovation at accessible prices.  For more information, please visit www.imprimispharma.com or www.GoDropless.com.

SAFE HARBOR

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, such as statements regarding, among other things, development of successful pharmacy operations, including quality assurance practices and policies that comply with applicable governmental standards; development and commercialization of the company's proprietary compounded formulations; development of a network of fulfillment pharmacies; the market potential for Imprimis' ophthalmology and planned urology business units and the company's ability to capture a significant share of these markets; plans to expand the ophthalmology business unit and the success of any such expansion; the launch of the company's planned urology business unit; research and development activities and the results of any studies or trials the company may conduct; protection of the company's intellectual property portfolio; and potential future acquisition and in-licensing activity and the success of any such activities. Forward looking statements are based on management's current expectations and assumptions and therefore are not guaranties of future performance and are subject to risks and uncertainties that may cause actual results to differ materially and adversely from those predicted by the forward looking statements.  Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its compounded formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; risks related to its compounding pharmacy operations; including its ability to maintain compliance with applicable state and federal laws and regulations; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential markets for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions.  As a result of to these risks and uncertainties, undue reliance should not be placed on forward looking statements.  You are encouraged to read Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, which more fully describe these and additional risks and uncertainties that may impact future performance. Such documents may be read free of charge on the SEC's web site at www.sec.gov. The limited information contained in this press release is not adequate for making an informed investment judgment. Forward looking statements speak only as of the date they are made and except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

[1] In April 2014, survey was conducted in Boston, MA at leading ophthalmology association meeting/convention.

CONTACT:
Andrew Boll
[email protected]
858.704.4042

SOURCE Imprimis Pharmaceuticals

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The cloud promises new levels of agility and cost-savings for Big Data, data warehousing and analytics. But it’s challenging to understand all the options – from IaaS and PaaS to newer services like HaaS (Hadoop as a Service) and BDaaS (Big Data as a Service). In her session at @BigDataExpo at @ThingsExpo, Hannah Smalltree, a director at Cazena, provided an educational overview of emerging “as-a-service” options for Big Data in the cloud. This is critical background for IT and data professionals...
"Once customers get a year into their IoT deployments, they start to realize that they may have been shortsighted in the ways they built out their deployment and the key thing I see a lot of people looking at is - how can I take equipment data, pull it back in an IoT solution and show it in a dashboard," stated Dave McCarthy, Director of Products at Bsquare Corporation, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
In his session at 19th Cloud Expo, Claude Remillard, Principal Program Manager in Developer Division at Microsoft, contrasted how his team used config as code and immutable patterns for continuous delivery of microservices and apps to the cloud. He showed how the immutable patterns helps developers do away with most of the complexity of config as code-enabling scenarios such as rollback, zero downtime upgrades with far greater simplicity. He also demoed building immutable pipelines in the cloud ...
The cloud competition for database hosts is fierce. How do you evaluate a cloud provider for your database platform? In his session at 18th Cloud Expo, Chris Presley, a Solutions Architect at Pythian, gave users a checklist of considerations when choosing a provider. Chris Presley is a Solutions Architect at Pythian. He loves order – making him a premier Microsoft SQL Server expert. Not only has he programmed and administered SQL Server, but he has also shared his expertise and passion with b...
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...
"IoT is going to be a huge industry with a lot of value for end users, for industries, for consumers, for manufacturers. How can we use cloud to effectively manage IoT applications," stated Ian Khan, Innovation & Marketing Manager at Solgeniakhela, in this SYS-CON.tv interview at @ThingsExpo, held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA.
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
@GonzalezCarmen has been ranked the Number One Influencer and @ThingsExpo has been named the Number One Brand in the “M2M 2016: Top 100 Influencers and Brands” by Onalytica. Onalytica analyzed tweets over the last 6 months mentioning the keywords M2M OR “Machine to Machine.” They then identified the top 100 most influential brands and individuals leading the discussion on Twitter.
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
Predictive analytics tools monitor, report, and troubleshoot in order to make proactive decisions about the health, performance, and utilization of storage. Most enterprises combine cloud and on-premise storage, resulting in blended environments of physical, virtual, cloud, and other platforms, which justifies more sophisticated storage analytics. In his session at 18th Cloud Expo, Peter McCallum, Vice President of Datacenter Solutions at FalconStor, discussed using predictive analytics to mon...
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of Soli...
Information technology is an industry that has always experienced change, and the dramatic change sweeping across the industry today could not be truthfully described as the first time we've seen such widespread change impacting customer investments. However, the rate of the change, and the potential outcomes from today's digital transformation has the distinct potential to separate the industry into two camps: Organizations that see the change coming, embrace it, and successful leverage it; and...
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service. In his session at 19th Cloud Exp...